Research progress of sodium-glucose cotransporter 2 inhibitors and autonomic nervous function in patients with heart failure
MEDS Basic Medicine · 2023
DOI: 10.23977/medbm.2023.010210 ↗Kurz gefasst
Fachartikel in der Zeitschrift MEDS Basic Medicine, 2023.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) seriously affects human health, and the autonomic nervous system disorder is an important basis for the occurrence and development of heart failure. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) was originally used to treat diabetes. Basic and clinical studies have reported that SGLT2i is effective in reducing the incidence of heart failure, hospitalization, and all-cause mortality in patients with or without diabetes mellitus. Because of its significant cardiovascular benefits, SGLT2i has been used as a guideline in the treatment of heart failure. The mechanisms by which SGLT2i improves heart failure include regulation of volume, cardio-renal mechanism, metabolic action, improvement of myocardial remodeling, reduction of inflammation and oxidative stress. Recent studies have found that SGLT2i is closely related to autonomic nervous function, and may be a new mechanism to improve heart failure. This article focuses on discussing the benefits of SGLT2i on heart failure and its effects on autonomic nervous system, providing a new basis for clinical treatment of heart failure.
Zitieren
APA
(2023). Research progress of sodium-glucose cotransporter 2 inhibitors and autonomic nervous function in patients with heart failure. MEDS Basic Medicine. https://doi.org/10.23977/medbm.2023.010210
Vancouver
Research progress of sodium-glucose cotransporter 2 inhibitors and autonomic nervous function in patients with heart failure. MEDS Basic Medicine. 2023. doi:10.23977/medbm.2023.010210
BibTeX
@article{euvimed2023,
title = {Research progress of sodium-glucose cotransporter 2 inhibitors and autonomic nervous function in patients with heart failure},
journal = {MEDS Basic Medicine},
year = {2023},
doi = {10.23977/medbm.2023.010210}
}
EUVIMED